Apposite's Life Sciences Investments
Ambit Biosciences Inc.
Investment: Lead investment in Series D
Date of investment: 2007
Investment status: Current
Location: San Diego, CA, USA
Website: www.ambitbio.com
Ambit Biosciences is a biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. Ambit has multiple drug candidates in clinical development, including Quizartinib a selective class III receptor tyrosine kinase inhibitor for treatment of acute myeloid leukaemia, currently in Phase II clinical trials.
Ambrx Inc.
Investment: Lead investment in Series C
Date of investment: 2006
Investment status: Current
Location: San Diego, CA, USA
Website: www.ambrx.com
Ambrx is a clinical stage biopharmaceutical company with a broad biologics platform that allows it to create best-in-class protein therapeutics, including improved versions of native proteins and therapeutic antibodies. Ambrx is advancing a robust portfolio of products spanning multiple therapeutic areas that are highly optimised for efficacy, safety and ease of use.
Anaphore Inc.
Investment: Series A Venture
Date of investment: 2009
Investment status: Current
Location: La Jolla, CA, USA
Website: www.anaphore.com
Anaphore is developing a novel class of protein therapeutics, Atrimers, to address significant unmet medical needs in immune-mediated diseases and oncology. Atrimers are thought to offer significant biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules.
Convergence Pharmaceuticals Limited
Investment: Series A Venture
Date of investment: 2010
Investment status: Current
Location: UK
Website: www.convergencepharma.com
Convergence Pharmaceuticals is focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, which was formed in September 2010, is an independent spin-out from GSK.
Pharmakodex Limited
Investment: Founding Series A co-investment
Date of investment: 2006
Investment status: Acquired
Location: Cambridge, UK
PharmaKodex is a specialty pharmaceuticals company developing small molecule drugs to treat pain and neurological conditions by using its proprietary drug delivery and formulation technologies. Pharmakodex was acquired by Swedish pharmaceutical company, Orexo AB (NASDAQ-OMX: ORX) in February 2009.
Serentis Limited
Investment: Founding Series A co-investment
Date of investment: 2006
Investment status: Past
Location: Cambridge, UK
Serentis was a biopharmaceutical company which aimed to develop a pipeline of innovative, proprietary products to address unmet medical needs in the dermatology field. Following the disappointed results of two of its clinical programmes, the company was placed into liquidation in June 2010 and the remaining cash was return to shareholders.